At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,053 enrolled
Drug / intervention
Empagliflozin/Linagliptindrug
Likely dose
Empagliflozin/Linagliptin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Esgliteo (Empagliflozin/Linagliptin, 10/5mg, 25/5mg) in Korean Patients With Type 2 Diabetes Mellitus
In Brief
An observational study evaluating Empagliflozin/Linagliptin for Diabetes Mellitus, Type 2. Completed, enrolled 1,053 participants across 30 sites.
Detailed Summary
The objectives of this study are to monitor the safety and effectiveness of Esgliteo in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartMar 2022
Primary CompletionApr 2024
Study CompletionJul 2024
TodayJul 2026
First PostedNov 23, 2021
Enrollment StartMar 22, 2022
Primary CompletionApr 8, 2024
Study CompletionJul 8, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 4.6 years ago
Interventions
Empagliflozin/Linagliptindrug
Participants received Empagliflozin 10mg or 25mg and Linagliptin 5mg (Fixed Dose) Film-coated tablets orally once daily with or without food.